Investigating African American-specific AD-related ABCA7 Variants Using Isogenic hiPSCs

Overview

Información sobre este estudio

In this proposal, we will generate hiPSCs from AA patients and use our TREE-based approaches to introduce AA-associated variants into isogenic hiPSCs. In turn, we will use these isogenic hiPSC lines in a 3-D cortical model to address the following hypothesis-testing questions: (1) Does the presence of specific ABCA7 variants modulate disease-related phenotypes in a hiPSC-based system? (2) Are the risk modifying effects of the ABCA7 variants mediated through cell-autonomous or non-autonomous mechanisms? (3) Do these ABCA7 variants exert their effects through modulation of Aβ processing, secretion, and uptake? (4) What is the effect of these ABCA7 variants as it relates to tau-phosphorylation? (5) Are there transcriptional targets that are independently influenced by the presence of specific ABCA7 variants? To address these questions, we will leverage the collaborative stem cell engineering and neurodegenerative disease modeling expertise of Dr. Brafman as well the clinical neurobiology expertise of Dr. Caselli in the following specific aims:

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • African American descent.
  • Minimum of 50 years of age.
  • Have neuropsychological documentation of their cognitive/clinical status.

Exclusion Criteria:

  • Less than 50 years of age.
  • Unwilling to provide consent.
  • Diagnostic uncertainty (which may be due to a complicating medical condition such as metastatic cancer, end stage organ disease, concurrent neuropsychiatric disease (or other medical factor). 

More information

Publicaciones

Publications are currently not available
.
CLS-20521066

Mayo Clinic Footer